$44.3 Million is the total value of Knoll Capital Management, LLC's 21 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALT | Altimmune Inc | $2,860,063 | +28.8% | 173,864 | 0.0% | 6.46% | +397.7% | |
| BAH | Booz Allen Hamilton HLDG CORcl a | $1,358,760 | +13.2% | 13,000 | 0.0% | 3.07% | +337.4% | |
| CVS | CVS Health Corp | $1,351,255 | -2.4% | 14,500 | 0.0% | 3.05% | +277.0% | |
| TMO | Thermo Fischer Scientific Inc | $1,156,449 | +8.5% | 2,100 | 0.0% | 2.61% | +318.9% | |
| MO | Altria Group Inc | $1,037,617 | +13.2% | 22,700 | 0.0% | 2.34% | +336.9% | |
| V | Visa | $1,007,636 | +16.9% | 4,850 | 0.0% | 2.27% | +351.2% | |
| BX | Blackstone Group LP | $741,900 | -11.5% | 10,000 | 0.0% | 1.67% | +241.6% | |
| OR | OSISKO GOLD ROYALTIES LTD | $607,710 | +14.9% | 235,000 | 0.0% | 1.37% | +343.7% | |
| SA | SEABRIDGE GOLD INC | $515,780 | +5.9% | 41,000 | 0.0% | 1.16% | +308.4% | |
| ENTX | Entera Bio Ltd | $2,584 | -99.9% | 2,484,275 | 0.0% | 0.01% | -99.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.